| 000 | 01821 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250517235546.0 | ||
| 264 | 0 | _c20191021 | |
| 008 | 201910s 0 0 eng d | ||
| 022 | _a1529-8027 | ||
| 024 | 7 |
_a10.1111/jns.12287 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRoux, Thomas | |
| 245 | 0 | 0 |
_aRituximab in chronic inflammatory demyelinating polyradiculoneuropathy with associated diseases. _h[electronic resource] |
| 260 |
_bJournal of the peripheral nervous system : JPNS _c12 2018 |
||
| 300 |
_a235-240 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAutoimmune Diseases _xcomplications |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 | _aDrug Evaluation |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 |
_aHematologic Diseases _xcomplications |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulins, Intravenous _xtherapeutic use |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeural Conduction |
| 650 | 0 | 4 |
_aPolyradiculoneuropathy, Chronic Inflammatory Demyelinating _xcomplications |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aRituximab _xtherapeutic use |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aDebs, Rabab | |
| 700 | 1 | _aMaisonobe, Thierry | |
| 700 | 1 | _aLenglet, Timothée | |
| 700 | 1 | _aDelorme, Cécile | |
| 700 | 1 | _aLouapre, Céline | |
| 700 | 1 | _aLeblond, Véronique | |
| 700 | 1 | _aViala, Karine | |
| 773 | 0 |
_tJournal of the peripheral nervous system : JPNS _gvol. 23 _gno. 4 _gp. 235-240 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/jns.12287 _zAvailable from publisher's website |
| 999 |
_c28824422 _d28824422 |
||